- Home
- DRH vs SLNO Comparison
DRH vs SLNO Comparison
Compare DRH & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRH
- SLNO
- Stock Information
- Founded
- DRH 2004
- SLNO 1999
- Country
- DRH United States
- SLNO United States
- Employees
- DRH N/A
- SLNO N/A
- Industry
- DRH Real Estate Investment Trusts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DRH Real Estate
- SLNO Health Care
- Exchange
- DRH Nasdaq
- SLNO Nasdaq
- Market Cap
- DRH 1.8B
- SLNO 1.9B
- IPO Year
- DRH 2005
- SLNO 2014
- Fundamental
- Price
- DRH $8.78
- SLNO $42.54
- Analyst Decision
- DRH Hold
- SLNO Strong Buy
- Analyst Count
- DRH 5
- SLNO 6
- Target Price
- DRH $10.25
- SLNO $74.83
- AVG Volume (30 Days)
- DRH 2.1M
- SLNO 587.8K
- Earning Date
- DRH 02-27-2025
- SLNO 03-05-2025
- Dividend Yield
- DRH 3.64%
- SLNO N/A
- EPS Growth
- DRH N/A
- SLNO N/A
- EPS
- DRH 0.29
- SLNO N/A
- Revenue
- DRH $1,114,379,000.00
- SLNO N/A
- Revenue This Year
- DRH N/A
- SLNO N/A
- Revenue Next Year
- DRH $2.74
- SLNO N/A
- P/E Ratio
- DRH $30.63
- SLNO N/A
- Revenue Growth
- DRH 4.50
- SLNO N/A
- 52 Week Low
- DRH $7.74
- SLNO $36.61
- 52 Week High
- DRH $10.00
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- DRH 34.89
- SLNO 32.60
- Support Level
- DRH $8.55
- SLNO $41.58
- Resistance Level
- DRH $9.00
- SLNO $46.82
- Average True Range (ATR)
- DRH 0.16
- SLNO 1.78
- MACD
- DRH -0.06
- SLNO -0.03
- Stochastic Oscillator
- DRH 26.16
- SLNO 17.27
About DRH Diamondrock Hospitality Company
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transient, business transient, and group customers.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.